The Potential Role of Vedolizumab in Concomitant Eosinophilic Esophagitis and Crohn’s Disease

Eosinophilic gastrointestinal disorders are challenging conditions with limited pharmacologic options that may decrease quality of life and increase health care utilization and costs.1 Kim et al2 present very interesting findings for the use of vedolizumab in a small cohort of 5 treatment-refractory patients with eosinophilic gastritis/gastroenteritis, showing clinical and histologic improvements. However, it is unknown if vedolizumab could be effective in esophageal manifestations of eosinophilic disease, such as intractable eosinophilic esophagitis (EoE).

https://ift.tt/2O2VMEJ